Muscarinic acetylcholine receptor-mediated activation of Gq in rat brain membranes determined by guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding using an anti-G protein scintillation proximity assay

被引:12
作者
Odagaki, Yuji [1 ]
Toyoshima, Ryoichi [1 ]
机构
[1] Saitama Med Univ, Fac Med, Dept Psychiat, Moroyama, Saitama 3500495, Japan
关键词
G proteins; Guanosine-5 '-O-(3-[S-35]thio)triphosphate ([(35) S]GTP gamma S) binding; Muscarinic acetylcholine receptors (mAChRs); Carbamylcholine chloride (CCh); Scintillation proximity assay (SPA); HAMSTER OVARY CELLS; PHARMACOLOGICAL CHARACTERIZATION; STRIATAL MEMBRANES; CEREBRAL-CORTEX; SUBTYPES; TOXINS; MT-7; M1;
D O I
10.1007/s00702-011-0742-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In the present study, we performed antibody-capture guanosine-5'-O-(3-[S-35]thio)triphosphate ([S-35]GTP gamma S) scintillation proximity assay (SPA), in which immuno-capture of G alpha subunits following [S-35]GTP gamma S binding was combined with SPA technology, in rat brain membranes. Preliminary experiments using a series of agonists and commercially available anti-G alpha antibodies indicated the increase in specific [S-35]GTP gamma S binding to G alpha(q) determined with the anti-G alpha antibody sc-393 and evoked by carbamylcholine chloride (CCh) was pharmacologically relevant. The experimental conditions were optimized as for the concentrations of GDP, MgCl2, and NaCl, the dilution of the anti-G alpha(q) antibody, and membrane protein contents incubated. Under the optimized conditions, CCh-stimulated specific [S-35]GTP gamma S binding to G alpha(q) in a concentration-dependent and saturable manner with an EC50 of around 10 mu M in all of the membranes prepared from rat hippocampus, cerebral cortex, and striatum. The maximum responses were varied according to the brain regions, with the rank order in magnitude of hippocampus > cerebral cortex > striatum. The addition of MT-7, a snake toxin with high selectivity for M-1 over the other muscarinic acetylcholine receptors (mAChRs) (M-2-M-5), almost completely extinguished CCh-stimulated [S-35]GTP gamma S binding to G alpha(q), even at a concentration as low as 1 nM. These results indicate that the functional coupling between M-1 mAChR and G alpha(q) can be investigated in rat native brain membranes by means of antibody-capture SPA/[S-35]GTP gamma S binding assay. The assay developed in the present study would provide a useful strategy for investigation of possible pathophysiological alterations in neuropsychiatric disorders such as Alzheimer's disease and schizophrenia as well as for drug discovery.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 29 条
[1]   Effects of muscarinic toxins MT2 and MT7, from green mamba venom, on m1, m3 and m5 muscarinic receptors expressed in Chinese Hamster Ovary cells [J].
Bradley, KN ;
Rowan, EG ;
Harvey, AL .
TOXICON, 2003, 41 (02) :207-215
[2]  
Caulfield MP, 1998, PHARMACOL REV, V50, P279
[3]   The antibody-capture [35S]GTP-γS scintillation proximity assay:: a powerful emerging technique for analysis of GPCR pharmacology [J].
DeLapp, NW .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (08) :400-401
[4]  
DeLapp NW, 1999, J PHARMACOL EXP THER, V289, P946
[5]  
Eglen RM, 2005, PROGR MED CHEM, V43, P105, DOI 10.1016/S0079-6468(05)43004-0
[6]   Therapeutic opportunities for muscarinic receptors in the central nervous system [J].
Felder, CC ;
Bymaster, FP ;
Ward, J ;
DeLapp, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (23) :4333-4353
[7]   The [35S]GTPγS binding assay:: approaches and applications in pharmacology [J].
Harrison, C ;
Traynor, JR .
LIFE SCIENCES, 2003, 74 (04) :489-508
[8]  
Kahl S. D., 2005, CURR PROTOC NEUROSCI
[9]   Snake toxins with high selectivity for subtypes of muscarinic acetylcholine receptors [J].
Karlsson, E ;
Jolkkonen, M ;
Mulugeta, E ;
Onali, P ;
Adem, A .
BIOCHIMIE, 2000, 82 (9-10) :793-806
[10]   Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex:: A scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists [J].
la Cour, C. Mannoury ;
Vidal, S. ;
Pasteau, V. ;
Cussac, D. ;
Millan, M. J. .
NEUROPHARMACOLOGY, 2007, 52 (03) :1003-1014